
Kamari Pharma Announces Closing of $23 Million Financing to Advance its First-In-Class Oral TRPV3 Inhibitor for Rare ...
Financing co-led by new investor BRM Group and existing investor Pontifax Lead program KM023 is a first-in-class oral TRPV3 inhibitor entering clinical development for the treatment of three rare genetic skin diseases; Olmsted syndrome, severe keratoderma …